Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia-Reference-Cited by-同舟云学术

Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia

Published:2022-08-23 Issue:1 Volume:58 Page:25-33
ISSN:0036-5521
Container-title:Scandinavian Journal of Gastroenterology
language:en
Short-container-title:Scandinavian Journal of Gastroenterology

Author:

Bjørlykke Kristin H.¹²^ORCID,Jahnsen Jørgen¹²^ORCID,Brynskov Jørn³,Molander Pauliina⁴,Eberhardson Michael⁵,Davidsdottir Loà G.⁶,Sipponen Taina⁴,Hjortswang Henrik⁵,Goll Guro Løvik⁷,Syversen Silje Watterdal⁷,Langholz Ebbe³⁸,Jørgensen Kristin K.¹,Steenholdt Casper³

Affiliation:

1. Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway

2. Institute of Clinical Medicine, University of Oslo, Oslo, Norway

3. Department of Gastroenterology, Herlev Hospital, Herlev, Denmark

4. Abdominal Center, Gastroenterology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland

5. Department of Gastroenterology, University Hospital, Linköping, Sweden and Karolinska Institutet, Stockholm, Sweden

6. Department of Gastroenterology, Landspítali, University Hospital of Iceland, Reykjavik, Iceland

7. Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway

8. Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

Publisher

Informa UK Limited

Subject

Gastroenterology

Link

https://www.tandfonline.com/doi/pdf/10.1080/00365521.2022.2108684

Reference40 articles.

1. Ulcerative colitis

2. Crohn's disease

3. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study

4. Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review

5. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative study of a point-of-care test and an enzyme-linked immunosorbent assay (ELISA) for infliximab levels;Scandinavian Journal of Gastroenterology;2023-10-26

2. 90K/Mac-2 BP Is a New Predictive Biomarker of Response to Infliximab Therapy in IBD Patients;International Journal of Molecular Sciences;2023-02-16